The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 02, 2020
Filed:
Jan. 05, 2018
Applicants:
Icahn School of Medicine AT Mount Sinai, New York, NY (US);
University of Kansas, Lawrence, KS (US);
Inventors:
John Cijiang He, New York, NY (US);
Ruijie Liu, New York, NY (US);
Bhaskar Das, Kansas City, KS (US);
Wenzhen Xiao, New York, NY (US);
Zhengzhe Li, New York, NY (US);
Kyung Lee, New York, NY (US);
Assignees:
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, New York, NY (US);
UNIVERSITY OF KANSAS, Lawrence, KS (US);
Primary Examiner:
Int. Cl.
CPC ...
C07D 271/04 (2006.01); C07D 271/06 (2006.01); C07D 271/08 (2006.01); C07D 271/107 (2006.01); C07D 413/04 (2006.01); C07F 5/04 (2006.01); A61P 13/12 (2006.01); C07D 413/14 (2006.01); C07F 5/02 (2006.01); C12N 9/99 (2006.01);
U.S. Cl.
CPC ...
C07D 413/04 (2013.01); A61P 13/12 (2018.01); C07D 271/04 (2013.01); C07D 271/06 (2013.01); C07D 271/08 (2013.01); C07D 271/107 (2013.01); C07D 413/14 (2013.01); C07F 5/02 (2013.01); C07F 5/025 (2013.01); C07F 5/04 (2013.01); C12N 9/99 (2013.01);
Abstract
Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.